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A B S T R A C T
Background: The signiﬁcance of routine measurement of lactate level is unclear in patients with critical
acute decompensated heart failure (ADHF).
Methods and results: Consecutive 754 patients who were admitted to the intensive care unit (ICU) in our
hospital from January 2007 to March 2012 and given a diagnosis of ADHF were eligible for retrospective
entry into the registry. Lactate level was measured on admission from routine arterial blood sample and
we investigated by comparing the lactate level and parameters of conventional in-hospital mortality
predictors. Among the patients, 88 (12%) died during hospitalization. The lactate level had great power to
predict in-hospital mortality, as suggested by the c-statistics of 0.71. The occurrence of in-hospital death
was more pronounced in patients with high levels of lactate (>3.2 mmol/l) and the tendency was
observed in patients in both the acute coronary syndrome (ACS) group and non-ACS group. In
multivariate analysis, elevated lactate levels remained an independent predictor of in-hospital death
(odds ratio, 2.14; 95% conﬁdence interval, 1.10–4.21; p = 0.03).
Conclusions: Elevated levels of arterial lactate on admission were related to worse in-hospital mortality
in patients with ADHF either with or without ACS, suggesting that the presence of high lactate in patients
who enter the ICU with ADHF could help stratify the initial risk of early mortality.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Heart failure has emerged over the past few decades as a major
public health problem, with rising prevalence [1]. Among heart
failure patients, visits to the emergency room are reportedly a
common occurrence and the majority of patients who present to
the emergency room with acute decompensated heart failure
(ADHF) syndrome are admitted to hospital [2,3]. Better under-
standing of the pathophysiology and more evidence of risk
stratiﬁcation in patients with ADHF are required.
In patients with ADHF, evaluation of the degree of decompen-
sation, especially the adequacy of tissue perfusion, is important [4].* Corresponding author at: Department of Cardiology, Tsuchiya General Hospital,
3-30, Nakajimacho, Nakaku, Hiroshima 730-8655, Japan. Tel.: +81 82 243 9191;
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsIn extreme cases, a marked tissue hypoperfusion due to low cardiac
output leads to impaired tissue oxygenation and elevation of
lactate. The use of lactate level for risk assessment has been
evaluated for acute myocardial infarction [5,6], but the signiﬁcance
of lactate level in the setting of ADHF has not been adequately
addressed. We investigated whether lactate level on admission in
patients with ADHF is related to early outcomes.
Methods
Eight hundred consecutive patients who were admitted to the
intensive care unit (ICU) in our hospital from January 2007 to
March 2012 and given a diagnosis of ADHF were eligible for
retrospective entry into the registry. ADHF was diagnosed
according to the Framingham criteria [7]. Patients were excluded
if blood gas analysis on admission was not available (n = 35) or if
cardiopulmonary arrest occurred on admission (n = 11) (Fig. 1). reserved.
Excluded pati ent s wit hout BG A: (35 pati ent s)
Excluded pati ent s who r ecovered fr om  cardioplu monary arrest: (11 pati ents)
800 patients with  ADHF who entered  the ICU. (January  2007  – March 201 2)
Study  Pop ulatio n 
754 consecutive  ADHF patients  who measured  the lacatate leve ls.
Fig. 1. Patient ﬂowchart for the present study. ADHF, acute decompensated heart failure; ICU, intensive care unit; BGA, blood gas analysis.
Table 1
Etiology of the patients in the study.
Variable n (%)
Overall n = 754
In-hospital death 88 (12)
ACS patients who underwent primary PCI 388 (52)
Etiology of non-ACS group n = 366
Ischemic heart disease 170 (46)
Hypertensive heart disease 70 (19)
Arrythmogenic heart disease 55 (15)
Valvular heart disease 35 (10)
Cardiomyopathy 28 (8)
Other 8 (3)
Data are number (percentage). ACS, acute coronary syndrome; PCI, percutane-
ous coronary intervention.
T. Kawase et al. / Journal of Cardiology 65 (2015) 164–170 165This left a total of 754 patients for inclusion, and their patient
demographics, medical history, clinical presentation, laboratory
results, treatment course, and clinical outcomes data were
collected by chart review. The study method was reviewed and
approved by the institute research ethics committee.
Patient measures and deﬁnition
The primary endpoint in this study was in-hospital death. All
patients underwent an initial clinical assessment that included
taking a clinical history, a physical examination, 12-lead electro-
cardiogram (ECG), continuous ECG monitoring, pulse oximetry,
standard blood measurements, echocardiography, and chest
radiography. A routine arterial blood sample was also obtained
immediately on presentation to the emergency room, and lactate
level was measured in the same specimen. Lactate was measured
within 5 min on an ABL 800 series analyzer (Radiometer,
Copenhagen, Denmark) with a lower detection limit of
0.1 mmol/l. Left ventricular ejection fraction (LVEF) was measured
at the time of admission via trans-thoracic echocardiography using
the Simpson method. Duration of both ICU stay and hospital stay
were recorded in days. Mechanical ventilation and mechanical
circulatory support were also recorded. To determine the etiology
of heart failure for each patient, all the available medical records
(the clinical history, ﬁndings on physical examination, and results
of laboratory tests, radiologic studies, ECG, echocardiography,
cardiac stress testing, coronary computed tomography angiogram,
and coronary angiography) were reviewed. An acute myocardial
infarction (AMI) was deﬁned in accordance with current guidelines
[8]. In brief, an AMI was diagnosed when there was evidence of
myocardial necrosis in association with clinical signs of myocardial
ischemia with at least one of the following: symptoms typical for
ischemia, new ECG change indicative of new ischemia, and/or
imaging evidence of new regional wall motion abnormality.
Necrosis was diagnosed on the basis of the cardiac troponin level,
with at least one value above the 99th percentile. Among AMI
patients, those with Killip classiﬁcation I were not included. All the
cases diagnosed as ACS were conﬁrmed by coronary angiogram.
Renal failure was deﬁned as estimated glomerular ﬁltration rate
(eGFR) < 30 ml/min per 1.73 m2 according to the Modiﬁcation of
Diet in Renal Disease study equation modiﬁed for Japanese
patients [9]. Positive inotropic therapy included continuous
intravenous administration of catecholamine or phosphodiester-
ase III inhibitor, and digitalis use was not included.
Statistical analysis
Categorical variables are presented as counts and/or percen-
tages in Tables 1–3 and were compared using the chi square test.
Continuous variables are expressed as mean  standard deviation
unless otherwise indicated, and were compared using the Student
t-test or Wilcoxon rank sum test on the basis of their distributions.
Receiver operating characteristic (ROC) curves were constructed to
assess the cut off point of lactate levels obtained at presentation andwe inferred their ability to predict the outcomes. Mortality after the
initial admission including death events that occurred after discharge
was analyzed using the Kaplan–Meier method and the log-rank test.
We used the logistic regression model to make adjusted comparisons
with and without elevation of lactate levels for in-hospital death. All
the variables in Table 3 were dichotomized by clinically meaningful
thresholds using ROC curves for death and were used as potential
risk-adjusting variables, and we selected those variables with a
univariate p-value <0.05 for the multivariate model. Because B-type
natriuretic peptide (BNP) and troponin-I had missing values that
cannot be ignored, these factors were separately analyzed in
subanalyses.
All the reported p-values are two-sided and p-values <0.05
were regarded as statistically signiﬁcant. We conducted all the
statistical analyses using JMP version 10.0 software (SAS Institute,
Inc., Cary, NC, USA).
Results
Patient characteristics
Patient characteristics are presented in Table 1. Among the total
study population, 388 (52%) were ACS patients and 368 (48%) were
non-ACS patients. Among non-ACS patients, 170 (46%) had chronic
coronary artery disease, 70 (19%) had hypertensive heart disease,
55 (15%) had arrythmogenic heart disease, 35 (10%) had valvular
heart disease, and 28 (8%) had cardiomyopathy; the remaining
patients (3%) were considered to have other causes of decom-
pensated heart failure (Table 1).
Of the 754 patients, 88 (12%) died during hospitalization.
Cardiac death occurred in 53 patients (60%) and non-cardiac death
occurred in 35 patients (40%; including 14 renal failure, 10
pneumonia, 8 sepsis, and 3 cerebrovascular events) (Table 2).
The clinical characteristics of the patients are presented in
Table 3. The non-survivor group was older, had a lower body mass
index (BMI), lower systolic blood pressure (SBP) on admission, and
a higher prevalence of renal failure and previous myocardial
Table 2
The causes of death in this study.
Overall Lactate > 3.2 mmol/l Lactate 2 3.2 mmol/l p-value
n = 754 n = 216 n = 538
All-cause death 88 (11.7) 52 (24.1) 36 (6.7) <0.0001
Cardiac death 53 (7.0) 34 (15.7) 19 (3.5) <0.001
Non-cardiac death 35 (4.6) 18 (8.3) 17 (3.2) 0.004
Renal failure 14 (1.9) 8 (3.7) 6 (1.1)
Pneumonia 10 (1.3) 4 (1.9) 6 (1.1)
Sepsis 8 (1.0) 4 (1.9) 4 (0.7)
Stroke 3 (0.4) 2 (0.8) 1 (0.2)
Values as number and percentage (%).
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support were more frequently used in the non-survivor group.
The non-survivor group also exhibited a lower LVEF on admission.
No differences were observed in the levels of sodium and glucose
between the two groups. The non-survivor group exhibited higher
levels of lactate, uric acid, troponin-I, C-reactive protein (CRP), and
BNP, and lower levels of hemoglobin and eGFR.
Risk stratiﬁcation with lactate levels
The ROC curves were constructed to assess the cut off point of
lactate obtained on admission and to compare their ability toTable 3
Patient characteristics according to patient survival in hospital.
Variable All patients 
n = 754 
Age (years) 73.2  12.3 
Male 427 (56.6) 
Days of ICU stay, median (IQR) 3 (2–5) 
Days of hospital stay, median (IQR) 19 (12–31) 
ACS patients who underwent primary PCI 388 (51.5) 
BMI (kg/m2) 23.3  4.8 
SBP (mmHg) 145  41 
Heart rate (beats/min) 90  29 
Hypertension 556 (75) 
Diabetes mellitus 317 (42) 
Dyslipidemia 445 (59) 
Atrial ﬁbrillation 125 (16.6) 
HD or CAPD 52 (6.9) 
Previous MI 186 (24.7) 
COPD 22 (2.9) 
LVEF 50.1  13.9 (n = 728) 
Lactate (mmol/l)
(median IQR)
3.0  2.8
2.1 (1.3–3.6)
Na (mmol/l) 138  4 
Glucose (mg/dl), median (IQR) 185 (141–260) 
Hb (g/dl) 12.5  2.3 
Uric acid (mg/dl) 6.2  2.1 
eGFR (ml/min/1.73 m2), median (IQR) 51.4 (31.4–69.8) 
Troponin-I (ng/ml), median (IQR) 0.14 (0.04–1.52) (n = 694) 
CRP (mg/dl), median (IQR) 0.46 (0.14–1.86) 
BNP (pg/ml), median (IQR) 448.1 (90.1–1341.7) (n = 603) 
Treatment
Mechanical ventilation 234 (31) 
Mechanical circulatory support 120 (15.9) 
Vasodilator 524 (69.5) 
Carperitide cases 384 (50.9) 
Nitrate cases 269 (35.7) 
Inotropic agents 244 (32.4) 
Dopamine 211 (28.0) 
Dobutamine 111 (14.7) 
Noradrenaline 36 (4.8) 
Phosphodiesterase III inhibitor 23 (3.1) 
Data are mean  standard deviation or number (percentage) unless otherwise indicated
IQR, interquartile range; ICU, intensive care unit; ACS, acute coronary syndrome; PCI, perc
HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; MI, myocardial infa
fraction; Hb, hemoglobin; eGFR, estimated glomerular ﬁltration rate; CRP, C-reactive prpredict in-hospital mortality. The area under the curve index
was 0.71. A lactate level of 3.2 mmol/l was chosen according to the
c-statistic as the best value able to discriminate between patients
who survived and patients who died during hospital stay, and
sensitivity and speciﬁcity were 60.2% and 74.6%, respectively
(Fig. 2).
Kaplan–Meier curves for all-cause mortality for 180 days after
admission according to lactate level are shown in Fig. 3A–C. The
occurrence of death was more pronounced in patients with high
levels of lactate (>3.2 mmol/l) (p < 0.0001) (Fig. 3A). This tendency
was observed in patients in both the ACS group and non-ACS
group (Fig. 3B and C). Then we analyzed the factors associated withSurvivors Non-survivors p-value
n = 666 n = 88
72.5  12.5 78.4  9.6 <0.0001
382 (57.4) 45 (51.1) 0.3
3 (2–4) 6 (2–11) <0.0001
19 (13–30) 15 (5–45) 0.01
351 (52.7) 37 (42.1) 0.07
23.5  4.9 21.4  3.2 <0.0001
148  41 123  39 <0.0001
90  29 93  30 0.33
448 (73.3) 68 (77.3) 0.52
283 (42.5) 34 (38.6) 0.57
401 (60.2) 44 (50) 0.08
108 (16.2) 17 (19.3) 0.45
40 (6.0) 12 (13.6) 0.01
155 (23.3) 31 (35.2) 0.02
19 (2.9) 3 (3.4) 0.73
50.8  13.8 (n = 659) 43.5  14.9 (n = 69) <0.0001
2.7  2.2
1.9 (1.3–3.2)
5.4  4.5
3.9 (1.9–7.6)
<0.0001
<0.0001
137.8  4.2 137  5.6 0.11
185 (141–260) 185 (140–249) 0.73
12.7  2.3 11.1  2.5 <0.0001
6.0  2.0 7.2  2.8 <0.0001
53.7 (37.4–71.5) 23 (11–44.2) <0.0001
0.12 (0.03–1.23) (n = 614) 0.43 (0.10–11.49) (n = 80) <0.0001
0.41 (0.12–1.325) 1.99 (0.29–4.89) <0.0001
391.9 (79–1232.1) (n = 546) 1117.9 (343–2037.7) (n = 57) <0.0001
174 (26.1) 60 (68.2) <0.0001
97 (14.6) 23 (26.1) 0.008
463 (69.5) 61 (69.3) 0.97
336 (50.5) 48 (54.6) 0.5
240 (36) 29 (33) 0.64
177 (26.6) 67 (76.1) <0.0001
153 (23.0) 58 (65.9) <0.0001
77 (11.6) 34 (38.6) <0.0001
13 (2.0) 23 (26.1) <0.0001
15 (2.3) 8 (9.1) 0.003
.
utaneous coronary intervention; BMI, body mass index; SBP, systolic blood pressure;
rction; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection
otein; BNP, B-type natriuretic peptide.
Fig. 2. Receiver operating characteristic (ROC) curve analysis of the lactate level
predicting in-hospital death. AUC, area under the curve.
Table 5A
Multivariate analyses for relation between in-hospital death and BNP level.
Variable Multivariate analysis p-value
OR (95% CI)
Lactate > 3.2 mmol/l 2.98 (1.51–6.01) 0.002
SBP > 140 mmHg 0.42 (0.20–0.86) 0.02
eGFR < 30 (ml/min/m2) 9.28 (4.50–20.14) <0.0001
Mechanical ventilation use 4.14 (1.99–8.89) 0.0001
Inotropic agent use 4.76 (2.34–10.14) <0.0001
BNP  800 0.99 (0.46–2.10) 0.99
Table 5B
Multivariate analyses for relation between in-hospital death and troponin-I level in
all patients.
Variable Multivariate analysis p-value
OR (95% CI)
Lactate > 3.2 mmol/l 2.83 (1.55–5.24) 0.0007
SBP > 140 mmHg 0.38 (0.20–0.71) 0.002
eGFR < 30 (ml/min/m2) 7.71 (4.25–14.42) <0.0001
Mechanical ventilation use 4.08 (2.15–7.90) <0.0001
Inotropic agent use 4.32 (2.28–8.45) <0.0001
Troponin-I > 0.1 ng/ml 1.70 (0.91–3.24) 0.10
Table 5C
Multivariate analyses for relation between in-hospital death and troponin-I level in
non-ACS patients.
Variable Multivariate analysis p-value
OR (95% CI)
Lactate > 3.2 mmol/l 3.22 (1.44–7.51) 0.004
SBP > 140 mmHg 0.31 (0.13–0.69) 0.004
eGFR < 30 (ml/min/m2) 8.41 (3.55–21.71) <0.0001
Mechanical ventilation use 3.96 (1.64–10.21) 0.002
Inotropic agent use 3.57 (1.60–8.29) 0.002
Troponin-I > 0.1 ng/ml 2.09 (0.91–5.02) 0.08
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analyses, high age, low BMI, previous myocardial infarction, low
hemoglobin, high uric acid, renal failure, high CRP, use of
mechanical ventilation, use of mechanical circulatory support,
and treatment with inotropic agents were positively associated
with in-hospital death and a high SBP was negatively correlated
with in-hospital death. In multivariate analysis, elevated
lactate levels (lactate >3.2 mmol/l) remained an independent
predictor of in-hospital death [odds ratio (OR), 2.14; 95%
conﬁdence interval (CI) 1.10–4.21; p = 0.03]. Elevated blood
pressure (SBP > 140 mmHg) (OR, 0.36; 95% CI 0.17–0.73;
p = 0.004), renal failure (eGFR < 30 ml/min/m2 (OR, 6.72; 95% CI
3.28–14.17; p < 0.0001), use of mechanical ventilation (OR, 3.76;
95% CI 1.87–7.76; p = 0.0002), and use of inotropic agents (OR,
5.99; 95% CI 2.87–13.10; p < 0.0001) were also independently
associated with in-hospital death.
As BNP and troponin-I had missing values that cannot be
ignored, we analyzed the values of BNP and troponin-I separately
in sub analyses (Table 5). After adjusting for elevated levels of BNP
or troponin-I, high levels of lactate remained an independent
predictor for in-hospital death. The BNP level was not signiﬁcantly
related to in-hospital mortality after adjustment for confounders
(Table 5A), but the elevated level of troponin-I showed a trendTable 4
Results of univariate and multivariate analyses of risk factors for in-hospital death.
Variable Univariate analysis 
OR (95% CI) 
Lactate > 3.2 mmol/l 4.42 (2.80–7.05) 
Age  75 2.19 (1.38–3.54) 
BMI  22 (kg/m2) 2.27 (1.45–3.59) 
SBP > 140 mmHg 0.33 (0.20–0.53) 
Previous MI 1.79 (1.11–2.86) 
Hb < 10 g/dl 3.71 (2.22–6.09) 
Uric acid  7.0 (mg/dl) 2.30 (1.46–3.62) 
eGFR < 30 (ml/min/m2) 6.30 (3.97–10.14) 
CRP  1.3 (mg/dl) 3.85 (2.42–6.17) 
Mechanical ventilation use 6.06 (3.78–9.92) 
Mechanical circulatory support use 2.08 (1.21–3.46) 
LVEF  45% 2.66 (1.61–4.43) 
Inotropic agent use 8.81 (5.33–15.1) 
OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; SBP, systolic blood p
hemoglobin; eGFR, estimated glomerular ﬁltration rate; CRP, C-reactive protein.toward signiﬁcance for increasing in-hospital death (Table 5B).
When patients were divided into two groups according to ACS,
elevated troponin level showed a tendency to be related to in-
hospital mortality in non-ACS patients with ADHF (Table 5C), but
not in patients with ACS (Table 5D).p-value Multivariate analysis p-value
OR (95% CI)
<0.0001 2.14 (1.10–4.21) 0.03
0.0008 1.59 (0.81–3.21) 0.18
0.0003 1.64 (0.87–3.11) 0.12
<0.0001 0.36 (0.17–0.73) 0.004
0.02 0.76 (0.36–1.52) 0.44
<0.0001 1.44 (0.67–3.04) 0.35
0.0003 0.86 (0.43–1.68) 0.67
<0.0001 6.72 (3.28–14.17) <0.0001
<0.0001 1.80 (0.92–3.50) 0.08
<0.0001 3.76 (1.87–7.76) 0.0002
0.009 0.64 (0.27–1.45) 0.29
0.0001 1.23 (0.63–2.40) 0.54
<0.0001 5.99 (2.87–13.10) <0.0001
ressure; MI, myocardial infarction; LVEF, left ventricular ejection fraction; Hb,
Table 5D
Multivariate analyses for relation between in-hospital death and troponin-I level in
ACS patients.
Variable Multivariate analysis p-value
OR (95% CI)
Lactate > 3.2 mmol/l 2.50 (0.99–6.36) 0.051
SBP > 140 mmHg 0.61 (0.22–1.61) 0.32
eGFR < 30 (ml/min/m2) 7.70 (3.02–20.72) <0.0001
Mechanical ventilation use 4.36 (1.62–12.29) 0.0003
Inotropic agent use 6.63 (2.14–23.61) 0.0009
Troponin-I > 0.1 ng/ml 1.12 (0.42–3.16) 0.82
OR, odds ratio; CI, conﬁdence interval; BNP, B-type natriuretic peptide; SBP,
systolic blood pressure; eGFR, estimated glomerular ﬁltration rate; ACS, acute
coronary syndrome.
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In this study, we found that elevated levels of arterial lactate on
admission were related to worse in-hospital mortality in patientsFig. 3. Kaplan–Meier curves of in-hospital survival rate (all-cause death) in patients wit
patients; (B) ACS group; (C) non-ACS group. ACS, acute coronary syndrome.with ADHF either with or without ACS. In addition, SBP, renal
failure, mechanical ventilation use, and positive inotropic agent
therapy were independently associated with early mortality.
Hyperlactatemia is known as a marker of the metabolic stress
response and its severity is associated with increased mortality in
critically ill patients; the clinical value of circulating lactate has
been extensively demonstrated in intensive care settings [10].
Patients with advanced heart failure may show decreased cardiac
output and a subsequent decline in tissue perfusion [11]. When
tissue perfusion is impaired during reduction of cardiac output in
patients with ADHF, decreased oxygen delivery induces muscle
cells to use glycolysis and produce lactate from pyruvate, and
blood lactate measurements can be used as an indicator of
hemodynamic impairment [12,13]. Such a risk assessment via the
measurement of lactate has been applied for AMI in the setting of
the coronary care unit or catheter laboratory. In patients with ST
elevation acute myocardial infarction (STEMI) and impaired
hemodynamics, increased arterial lactate levels were associated
with early mortality [5] even after primary percutaneous coronaryh a lactate level 3.2 mmol/l and in those with a lactate level >3.2 mmol/l. (A) All
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STEMI, 12-h lactate clearance of <10% by serial measurement
identiﬁed a subset of patients at a higher risk for death in both
short and long terms [14].
In this study, we measured lactate levels in ADHF patients with
or without ACS in the emergency room setting. In this study
population, an elevated lactate was independently associated
with early in-hospital death in ADHF patients either with or
without ACS. Moreover, in surviving patients, those with elevated
lactate levels had a longer hospital stay than patients without
lactate elevation [median 25 interquartile range (15–40) days vs.
18 (13–27) days, p < 0.0001], suggesting that elevated lactate
levels were predictive of early mortality and the severity of ADHF.
In ADHF patients, elevated lactate levels may indicate
decreased oxygen delivery due to reduced cardiac output and
subsequent tissue hypo-perfusion. Positive inotropic therapy is
assumed to improve these conditions by increasing cardiac
output [15]. However, in this study population, the use of
positive inotropic agents was an independent predictor of
elevated in-hospital mortality rate. When patients were divided
into those with and without lactate elevation, therapy with an
inotropic agent was associated with a high in-hospital mortality
rate in both groups (>3.2 mmol/l) (10/107 vs. 42/109; p < 0.0001
in patients with elevated lactate level, 11/403 vs. 25/135;
p < 0.0001 in patients without elevated lactate level; p for
interaction = 0.60). Previous studies have also reported that
positive inotropic therapy was associated with an adverse early
mortality rate in patients hospitalized with ADHF [16]. Positive
inotropic agents may induce an increase in myocardial oxygen
consumption, heart rate, and risk of arrhythmias in patients with
ADHF. Thus the routine use of inotropic agents is not recom-
mended for ADHF patients with an elevated lactate level, and
indications for positive inotropic therapy should be individualized.
Systolic hypertension is common in patients hospitalized for
heart failure. Systolic blood pressure is an independent predictor of
morbidity and mortality in heart failure patients with either
reduced or relatively preserved systolic function [17]. Highsystolic
blood pressure (>140 mmHg) on hospital admission also identiﬁed
patients who had a favorable prognosis in this study population. In
patients with high SBP, acute ﬂuid redistribution due to after load
mismatch may be more pronounced, indicating that the duration
of decompensation prior to the admission is possibly shorter as
compared with those in patients without high blood pressure.
However, among patients with elevated blood pressure on
admission, high lactate levels remained a risk for high in-hospital
mortality (13/97 in patients with lactic level >3.2 mmol/l
vs. 12/291 with lactic levels 3.2 mmol/l, p = 0.003). These ﬁndings
suggest the importance of the measurement of lactate levels even
in ADHF patients presenting with high SBP.
The measurement of cardiac biomarkers is currently essential
to the diagnosis and evaluation of acute heart failure patients. BNP
measurement has been shown to facilitate the diagnosis and risk
stratiﬁcation of ADHF patients in the emergency room [18]. BNP is
secreted from the heart in response to cardiac hemodynamic stress
mediated by volume and/or pressure overload and BNP measure-
ments on admission are used for risk stratiﬁcation irrespective of
the cause [18]. Cardiac troponin testing is also commonly
performed in patients with heart failure [19]. A detectable baseline
level of troponin is possibly the result of physiological loss of
myocardium by necrosis and apoptosis and plays a central role in
the current diagnosis of AMI [8]. In patients with ADHF, reasons for
the higher prevalence of troponin remain uncertain but it has been‘
speculated that an increased ventricular preload causing myocar-
dial strain may cause troponin release [20]. The ADHERE Registry
[21] examined 67 924 ADHF patients and explored the relationship
between elevated troponin concentrations and adverse events.BNP and cardiac troponin levels on admission are signiﬁcant,
independent predictors of in-hospital mortality in acutely
decompensated HF [22]. In this study, the measurement of lactate
was independent of those parameters and thus routine measure-
ment of lactate in addition to cardiac biomarkers is recommended
in patients with ADHF.
In this study population, a large proportion of patients had
severe decompensation and few patients had mild ADHF. Such a
population bias may have contributed to the negative result of
some established risk factors in ADHF patients (e.g. BNP,
hyponatremia) [4,23].
Study limitations
There are several limitations to this study. First, this
study population has a possible selection bias. In this study, a
large proportion of patients had severe decompensation and a few
patients had mild ADHF because the candidates were ADHF
patients who required intensive care. Second, lactate was not
measured on admission in 4% of eligible patients. Third, in this
study, we focus on the relationship between lactate levels and
initial achievement of heart failure compensation, so the
inﬂuences of lactate level for long-term outcomes were not
assessed. Fourth, on assumption that lactate levels can reﬂect the
possible low perfusion of end-organs, the relation between
physically assessed low-perfusion patients as ‘clod’ forearms
and legs [11] and lactate levels may provide additive information.
But this issue was not assessed.
Conclusions
Elevated levels of arterial lactate on admission were related to
worse in-hospital mortality in patients with ADHF either with or
without ACS. In addition, SBP, renal failure, use of mechanical
ventilation, and positive inotropic agent therapy were indepen-
dent predictors for in-hospital mortality.
These ﬁndings suggest that the presence of high lactate in
patients who enter the ICU with ADHF could help stratify the initial
risk of early mortality.
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